New Combo Therapy TG-1101 + TGR-1202 - CLL Support
New Combo Therapy TG-1101 + TGR-1202
You need to be a member of this community to see this post.
Read more about...
4 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Zanubrutinib-Gazyva Shows Promise for CLL/SLL
June 25, 2019
Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s...
BTK Degrader Shows Potential for Treating Refractory CLL and SLL
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients...
Survey for CLL patients having taken Venetoclax or Acalabrutinib
CLL/SLL Patient Survey
If you have CLL or SLL and have been treated with the following therapies,...
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
Related Posts
Help!!! Incorrect diagnosis???- Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL
- BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
CT scan 2015 info update #1
Drug Trial update - Gazyva with TGR-1202
